Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Valbonne, FRA
Les Cardoulines HT1
Allée de la Nertière, Sophia-Antipolis,
Valbonne, 06560, FRA

People

Funding

TOTAL $16.1M
FUNDING TOTAL $16.1M
Series C, 11/2012
InnoBio Fund
Auriga Partners
Seventure Partners
€12.4M

Tags

TxCell

TxCell, a spin off of Inserm (France’s National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn’s disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.

Recent Milestones

Videos

Screenshots

Sources

  1. TxCell Raises €12.4M in Third Financing (finsmes.com) [edit]
Edit This Page
Last Edited 3/28/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy